At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Meclofenamic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders
The University of Texas Health Science Center, Houston·interventional·Posted Oct 11, 2016·Updated Mar 26, 2019
In Brief
A Phase 2 clinical trial evaluating Meclofenamic acid and Pentosan polysulfate sodium for Psychotic Disorders and 3 related conditions. Completed, enrolled 8 participants across 1 site.
Detailed Summary
This study evaluates the feasibility of administering meclofenamic acid or pentosan polysulfate sodium as an adjunctive treatment to patients diagnosed with a psychotic disorder. Half of participants will receive meclofenamic acid, while the other half will receive polysulfate sodium.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
Primary CompletionOct 2016
First PostedOct 2016
TodayJul 2026
First PostedOct 11, 2016
Enrollment StartAug 7, 2015
Primary CompletionOct 6, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.7 years ago
Interventions
Meclofenamic aciddrug
Pentosan polysulfate sodiumdrug